Search

Investors
Australia offers a wealth
of opportunities

utility-emailutility-printutility-pdfContact usChange to standard fontChange to large font

Investor UpdatesClick to subscribe to this Investor Updates RSS feed

Dutch pharmaceutical company opens $62m facility in Australia

14 November 2013

DSM Pharmaceutical Products has opened a new state-of-the-art biomanufacturing facility in Australia, underpinning the nation’s reputation for world-class medical innovation.

DSM Pharmaceutical Products is wholly owned by Dutch company Royal DSM, which said the plant would custom-make drugs on contract for local companies.

The $62 million facility in the Queensland capital of Brisbane was built in partnership with Biopharmaceuticals Australia with co-operation from the Queensland Government and the Australian Government, DSM said.

Royal DSM is one of the most recent overseas companies to establish or expand its research and development (R&D) capabilities in Australia in collaboration with the nation’s world-class research organisations and institutions.

“This world-class operation in the Asia-Pacific region is an important growth area in DSM's strategic development in the biopharmaceutical field,” the company said in a statement.

The Brisbane facility provides contract manufacturing services from process development to commercial manufacturing. It specialises in cGMP mammalian cell culture, used in the development of medicines to treat cancer and other illnesses.

"With its flexible design and use of single-use technology, the facility represents the model for the future of biomanufacturing,” said Lukas Utiger, DSM Pharmaceutical Products President and Chief Executive.

“It represents an important milestone in the development of Australia-based mammalian cell-based manufacturing of biopharmaceuticals, and extends DSM's contribution to the global biotechnology market," Mr Utiger said.

DSM will implement industry-standard technologies there, as well its own innovative proprietary technologies, the company said.

It has so far secured contracts with DecImmune Therapeutics of Cambridge, Massachusetts and RECEPTA Biopharma in São Paulo, Brazil; as well as Paranta Biosciences and Opthea, both of Melbourne.

Netherlands-based Royal DSM is a global science-based company active in health, nutrition and materials. Its products include food, dietary supplements, personal care, pharmaceuticals and medical devices. DSM's 23,500 employees deliver annual net sales of around €9 billion (A$9.2 billion) The company is listed on NYSE Euronext.

More information

Site Information

Austrade makes no warranty, express or implied as to the fitness for a particular purpose, or assumes any legal liability for the accuracy or usefulness of any information contained in this document. Any consequential loss or damage suffered as a result of reliance on this information is the sole responsibility of the user.